SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that members of its senior management team will present and participate the following upcoming investor conferences: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th at 2:30 pm Eastern TimeTD Cowen's 45th Annual Health Care Conference on March 3rd ...

Investors might want to bet on Lyell Immunopharma (LYEL) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inve ...

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early 2026Presenting additional data from the ongoing Phase 1-2 trial in 3rd line+ setting and initial clinical data in 2nd line setting in mid-2025Discontinuing development of LYL119, a ROR1-targeting CAR T-cell product candidate for solid tumors, to focus resources on acceleration of pivotal trials of IMPT-314 and next-generati ...

Lyell Immunopharma (LYEL) has been beaten down lately with too much selling pressure. While the stock has lost 31.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscill ...

Lyell Immunopharma (LYEL) has been on a downward spiral lately with significant selling pressure. After declining 30.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a ...

Lyell Immunopharma (LYEL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual in ...

Table of Contents __________________________ __________________________ __________________________ __________________________ __________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 1 ...

Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 • Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell nonHodgkin's lymphoma • Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024 (ASH) Annual Meeting • Pr ...

Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3rd line setting with B-cell non-Hodgkin lymphoma who have not yet been exposed to CAR T-cell therapySumant Ramachandra, M.D., Ph.D., MBA, appointed to Lyell’s Board of Directors SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) --  Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell ...

Company Overview - Lyell Immunopharma is a clinical-stage T-cell reprogramming company focused on developing cell therapies for solid tumors and hematologic malignancies [3] - The company has three product candidates in or entering Phase 1 clinical development [3] - Lyell's proprietary technology addresses T-cell exhaustion and lack of durable stemness to improve clinical outcomes [3] - The company is headquartered in South San Francisco, California with additional facilities in Seattle and Bothell, Washington [3] Upcoming Event - Lyell's President & CEO, Lynn Seely, MD, will participate in a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1, 2024, at 11:50 a.m. ET [1] - A webcast of the presentation will be available on the company's website, with a replay accessible after the live event [2]